Orphan Drug Credit in 2026: Global Policy Shifts and Australia’s Position

Orphan drug credits are financial incentives designed to stimulate the development of treatments for rare diseases. These incentives typically take the form of tax credits on eligible research and development (R&D) expenses, helping to offset the high costs and risks associated with bringing new therapies to market for small patient populations.

The Global Landscape in 2026

United States

The United States established the Orphan Drug Act in 1983, which introduced a tax credit for qualified clinical testing expenses related to orphan drugs. As of 2026, the US continues to offer a tax credit for a portion of these expenses, alongside other measures such as market exclusivity and fee waivers. Recent policy updates have focused on increasing transparency and ensuring that incentives are used appropriately. Broader healthcare reforms, such as those affecting drug pricing, are also influencing how companies approach orphan drug development.

European Union

The European Union provides a combination of incentives for orphan drugs, including tax benefits, market exclusivity, and reduced regulatory fees. In 2026, the EU is reviewing its incentive framework to address concerns about affordability and equitable access, while still encouraging innovation in rare disease treatments.

Japan

Japan offers a suite of incentives for orphan drug development, including a substantial tax credit for clinical trial expenses, priority review, and subsidies. These measures have helped position Japan as a leader in rare disease research and drug approval.

Australia does not currently have a dedicated orphan drug tax credit. Instead, companies involved in rare disease research can access the broader R&D Tax Incentive, which provides a refundable tax offset for eligible R&D activities. However, this incentive is not specifically tailored to the unique challenges of orphan drug development.

In 2026, the Australian government has initiated a review into the competitiveness of its biopharmaceutical incentives. This review is considering whether more targeted support for orphan drug development is needed to keep pace with international trends and to foster local innovation.

Key Issues Under Discussion

• Targeted Tax Credits: There is debate over whether Australia should introduce a specific orphan drug credit, similar to those in the US or Japan, to directly support rare disease research.
• Market Exclusivity and Fast-Track Approvals: Policymakers are considering whether enhanced exclusivity periods or expedited regulatory pathways could make Australia a more attractive destination for rare disease research and investment.
• Balancing Incentives and Access: Ensuring that incentives for companies do not compromise affordability and access for patients is a central concern. The policy debate is focused on finding a balance between encouraging innovation and protecting public health budgets.

Industry groups and patient advocates argue that more targeted incentives could help address the unmet needs of Australians living with rare diseases. However, any new measures will need to be weighed against fiscal constraints and the broader goals of the healthcare system.

The experience of pharmaceutical companies in countries with dedicated orphan drug credits demonstrates the potential benefits of such policies. In the United States, the orphan drug credit has supported the development of new treatments for a range of rare conditions, contributing to both improved patient outcomes and commercial success for innovative firms. In Japan, a combination of tax credits and regulatory support has enabled local companies to bring more orphan drugs to market.

For Australian biotech firms, the absence of a dedicated orphan drug credit means they may face challenges in attracting investment and competing with companies based in jurisdictions offering more direct support. Investors are increasingly attentive to global policy trends, and the presence or absence of targeted incentives can influence decisions about where to allocate capital.

Considerations for Stakeholders

• Startups and Small Companies: Early-stage firms may find it difficult to secure funding for high-risk rare disease research without targeted government support.
• Investors: The global policy environment is a key factor in investment decisions, with direct credits often seen as a catalyst for early-stage biotech investment.
• Patients: Ultimately, the goal of these incentives is to increase the availability of treatments for rare diseases. However, improved access depends not only on the development of new drugs but also on affordability and timely approval.

As global orphan drug policies continue to evolve, Australia faces important decisions about how to support rare disease innovation. The outcome of the current government review will determine whether Australia introduces a dedicated orphan drug credit or seeks alternative ways to encourage investment in this area.

With established models in the US and Japan, and ongoing reforms in the EU, Australian stakeholders—including pharmaceutical companies, investors, advocacy groups, and patients—are actively participating in the policy conversation. The direction Australia takes will influence its ability to attract biotech investment, retain local talent, and improve outcomes for people living with rare diseases.

In the interim, Australian companies may look to international collaborations or seek to benefit from overseas incentives. However, this approach carries the risk of shifting innovation and intellectual property offshore. The decisions made in 2026 will be critical in shaping whether Australia becomes a leader in rare disease research or continues to follow global trends.

The landscape for orphan drug credits is shifting worldwide, with significant implications for research, investment, and patient care. As Australia reviews its approach in 2026, the choices made will determine the country’s role in the future of rare disease treatment. The coming months will be pivotal for policymakers, industry, and patients alike.